Shire's Gaucher's drug meets primary endpoint in Phase III trial
This article was originally published in Scrip
Executive Summary
Shire's Gaucher's disease drug velaglucerase alfa met its primary endpoint in a Phase III trial, according to preliminary data. In light of shortages of Genzyme's Gaucher's disease treatment Cerezyme (imiglucerase), the US FDA has accepted a treatment protocol for velaglucerase alfa, adds Shire, which will enable physicians to treat Gaucher's disease patients before the drug's commercialisation.